Literature DB >> 8092833

Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

D S Kernodle1, A B Kaiser.   

Abstract

Recent shifts in the species and antibiotic resistance patterns of bacteria causing nosocomial infections present new challenges for providing effective prophylaxis in surgery. Traditional regimens lack activity against methicillin-resistant staphylococci and many gram-negative species causing nosocomial infections. The new fluoroquinolones exhibit in vitro activity against many emerging surgical wound pathogens. To determine the potential of this class of antimicrobial agents for use in surgery, we compared the prophylactic efficacies of ciprofloxacin and ofloxacin with those of cefazolin and vancomycin in a guinea pig model of abscess formation. Four Staphylococcus aureus strains, one Staphylococcus epidermidis strain, and one Staphylococcus haemolyticus strain were evaluated. Vancomycin was the most effective prophylactic agent, exhibiting in vivo activity against all strains which was superior or equivalent to those of all other agents tested. Cefazolin was the least effective agent and surpassed the two quinolones in prophylactic efficacy against only one organism, a quinolone- and methicillin-resistant strain of S. aureus. The two quinolones provided excellent protection against infection with all but the quinolone-resistant isolate. The in vivo emergence of quinolone resistance among quinolone-susceptible isolates was not detected. The methicillin-resistant, quinolone-susceptible S. epidermidis and S. haemolyticus isolates were extremely susceptible to prophylaxis, exhibiting 50% infective doses above 4 x 10(6) CFU for seven of the eight antibiotic-strain combinations. We conclude that ciprofloxacin and ofloxacin may be effective antistaphylococcal agents in surgery. The role of these agents remains to be defined, and the definition should include consideration of an adverse effect upon antibiotic resistance patterns of organisms causing nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092833      PMCID: PMC188206          DOI: 10.1128/AAC.38.6.1325

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Use of antimicrobial drugs in general hospitals: patterns of prophylaxis.

Authors:  M Shapiro; T R Townsend; B Rosner; E H Kass
Journal:  N Engl J Med       Date:  1979-08-16       Impact factor: 91.245

2.  Enteritis and coliform bacteremia in guinea pigs given penicillin.

Authors:  W E Farrar; T H Kent
Journal:  Am J Pathol       Date:  1965-10       Impact factor: 4.307

3.  In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci.

Authors:  B D Foleno; S C Lafredo; K P Fu
Journal:  Chemotherapy       Date:  1993 Mar-Apr       Impact factor: 2.544

4.  Automated fluorescence polarization immunoassay for monitoring vancomycin.

Authors:  K S Schwenzer; C H Wang; J P Anhalt
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

5.  In vitro activity of cefmenoxime, cefotaxime, latamoxef, cefazolin, nafcillin and vancomycin against 53 endocarditis and bacteremic strains of Staphylococcus aureus.

Authors:  V K Dhawan; M K Maier; M Nayyar; S K Chuah; H Thadepalli
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

6.  Antibiotic prophylaxis in neurosurgery. A randomized controlled trial.

Authors:  J Geraghty; M Feely
Journal:  J Neurosurg       Date:  1984-04       Impact factor: 5.115

7.  Hazards of rapid administration of vancomycin.

Authors:  P Newfield; M F Roizen
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

8.  Outline of details for official microbiological assays of antibiotics.

Authors:  A Kirshbaum; B Arret
Journal:  J Pharm Sci       Date:  1967-04       Impact factor: 3.534

9.  Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Gentamicin use and Pseudomonas and Serratia resistance: effect of a surgical prophylaxis regimen.

Authors:  N J Roberts; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

View more
  6 in total

1.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

2.  Synergism between poly-(1-6)-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranose glucan and cefazolin in prophylaxis of staphylococcal wound infection in a guinea pig model.

Authors:  A B Kaiser; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection.

Authors:  D S Kernodle; H Gates; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horses.

Authors:  James A Orsini; Corinna Snooks-Parsons; Lynne Stine; Marie Haddock; Charles F Ramberg; Charles E Benson; David M Nunamaker
Journal:  Can J Vet Res       Date:  2005-10       Impact factor: 1.310

Review 5.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

6.  Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  A Cagni; C Chuard; P E Vaudaux; J Schrenzel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.